These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Mechanisms and consequences of fibrosis in systemic sclerosis. Denton CP; Black CM; Abraham DJ Nat Clin Pract Rheumatol; 2006 Mar; 2(3):134-44. PubMed ID: 16932673 [TBL] [Abstract][Full Text] [Related]
43. The Exciting Future for Scleroderma: What Therapeutic Pathways Are on the Horizon? Distler JHW; Riemekasten G; Denton CP Rheum Dis Clin North Am; 2023 May; 49(2):445-462. PubMed ID: 37028846 [TBL] [Abstract][Full Text] [Related]
44. Scleroderma--clinical and pathological advances. Denton CP; Black CM Best Pract Res Clin Rheumatol; 2004 Jun; 18(3):271-90. PubMed ID: 15158741 [TBL] [Abstract][Full Text] [Related]
45. [Coexistence of scleroderma-like syndrome and idiopathic myelofibrosis in a 54-year-old female patient: case report]. Domysławska I; Ciołkiewicz M; Kowal-Bielecka O; Lewszuk A; Klimiuk PA; Sierakowski S Pol Arch Med Wewn; 2007 Aug; 117(8):370-3. PubMed ID: 18018385 [TBL] [Abstract][Full Text] [Related]
47. Targeted therapy for systemic sclerosis. Steen V Autoimmun Rev; 2006 Feb; 5(2):122-4. PubMed ID: 16431341 [TBL] [Abstract][Full Text] [Related]
48. Targeted therapy comes of age in scleroderma. Denton CP; Black CM Trends Immunol; 2005 Nov; 26(11):596-602. PubMed ID: 16168710 [TBL] [Abstract][Full Text] [Related]
49. Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials. Roofeh D; Lescoat A; Khanna D Expert Opin Emerg Drugs; 2020 Dec; 25(4):455-466. PubMed ID: 33054463 [TBL] [Abstract][Full Text] [Related]
50. The evolving pharmacotherapy of pulmonary fibrosis. Lota HK; Wells AU Expert Opin Pharmacother; 2013 Jan; 14(1):79-89. PubMed ID: 23265249 [TBL] [Abstract][Full Text] [Related]
51. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O; Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885 [TBL] [Abstract][Full Text] [Related]
53. Animal models of scleroderma: lessons from transgenic and knockout mice. Derrett-Smith EC; Denton CP; Sonnylal S Curr Opin Rheumatol; 2009 Nov; 21(6):630-5. PubMed ID: 19730378 [TBL] [Abstract][Full Text] [Related]
54. Practical approach to the therapy of systemic sclerosis. Czirják L Z Rheumatol; 2004 Dec; 63(6):451-6. PubMed ID: 15605208 [TBL] [Abstract][Full Text] [Related]
55. Recent advances in the treatment of systemic sclerosis. Bournia VK; Vlachoyiannopoulos PG; Selmi C; Moutsopoulos HM; Gershwin ME Clin Rev Allergy Immunol; 2009 Jun; 36(2-3):176-200. PubMed ID: 19132559 [TBL] [Abstract][Full Text] [Related]
56. Systemic and localized scleroderma. Chung L; Lin J; Furst DE; Fiorentino D Clin Dermatol; 2006; 24(5):374-92. PubMed ID: 16966019 [TBL] [Abstract][Full Text] [Related]
57. Endothelin receptor selectivity: evidence from in vitro and pre-clinical models of scleroderma. Shiwen X; Leask A; Abraham DJ; Fonseca C Eur J Clin Invest; 2009 Jun; 39 Suppl 2():19-26. PubMed ID: 19335743 [TBL] [Abstract][Full Text] [Related]
58. [Systemic sclerosis : What is currently available for treatment?]. Becker MO Internist (Berl); 2016 Dec; 57(12):1155-1163. PubMed ID: 27796473 [TBL] [Abstract][Full Text] [Related]
59. T cells and B cells in the pathogenesis of systemic sclerosis: recent insights and therapeutic opportunities. Del Galdo F; Artlett CM Curr Rheumatol Rep; 2006 Apr; 8(2):123-30. PubMed ID: 16569371 [TBL] [Abstract][Full Text] [Related]
60. Risk factors for severity and manifestations in systemic sclerosis and prediction of disease course. Becker MO; Riemekasten G Expert Rev Clin Immunol; 2016; 12(2):115-35. PubMed ID: 26558747 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]